Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

126 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Eribulin mesylate for the treatment of breast cancer.
Cigler T, Vahdat LT. Cigler T, et al. Among authors: vahdat lt. Expert Opin Pharmacother. 2010 Jun;11(9):1587-93. doi: 10.1517/14656566.2010.486790. Expert Opin Pharmacother. 2010. PMID: 20450446 Review.
Systemic adjuvant therapy of breast cancer.
Garrett TJ, Vahdat LT, Kinne DW. Garrett TJ, et al. Among authors: vahdat lt. J Surg Oncol. 1997 Feb;64(2):167-72. doi: 10.1002/(sici)1096-9098(199702)64:2<167::aid-jso16>3.0.co;2-3. J Surg Oncol. 1997. PMID: 9047258 Review.
Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
Papadopoulos KP, Ayello J, Tugulea S, Heitjan DF, Williams C, Reiss RF, Vahdat LT, Suciu-Foca N, Antman KH, Hesdorffer CS. Papadopoulos KP, et al. Among authors: vahdat lt. J Hematother. 1997 Feb;6(1):61-8. doi: 10.1089/scd.1.1997.6.61. J Hematother. 1997. PMID: 9112219 Clinical Trial.
Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Vahdat LT, Papadopoulos K, Balmaceda C, McGovern T, Dunleavy J, Kaufman E, Fung B, Garrett T, Savage D, Tiersten A, Ayello J, Bagiella E, Heitjan D, Antman K, Hesdorffer C. Vahdat LT, et al. Clin Cancer Res. 1998 Jul;4(7):1689-95. Clin Cancer Res. 1998. PMID: 9676843 Clinical Trial.
CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Papadopoulos KP, Ayello J, Reiss RF, Troxel A, Kaufman E, Vahdat LT, Antman KH, Hesdorffer CS. Papadopoulos KP, et al. Among authors: vahdat lt. J Hematother Stem Cell Res. 1999 Aug;8(4):357-63. doi: 10.1089/152581699320117. J Hematother Stem Cell Res. 1999. PMID: 10634173 Clinical Trial.
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
Papadopoulos KP, Egorin MJ, Huang M, Troxel AB, Kaufman E, Balmaceda CM, Vahdat LT, Hesdorffer CS. Papadopoulos KP, et al. Among authors: vahdat lt. Cancer Chemother Pharmacol. 2001;47(1):45-50. doi: 10.1007/s002800000193. Cancer Chemother Pharmacol. 2001. PMID: 11221961 Clinical Trial.
Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Vahdat LT, Balmaceda C, Papadopoulos K, Frederick D, Donovan D, Sharpe E, Kaufman E, Savage D, Tiersten A, Nichols G, Haythe J, Troxel A, Antman K, Hesdorffer CS. Vahdat LT, et al. Bone Marrow Transplant. 2002 Aug;30(3):149-55. doi: 10.1038/sj.bmt.1703592. Bone Marrow Transplant. 2002. PMID: 12189532 Clinical Trial.
126 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page